

A Fully Integrated and Automated Platform for Screening Biologics

Alex Zhai^{1,2}, Maria Basanta², Behnam Keshavarz¹, Joshua Justice¹, Gihoon Lee¹, Hirsh Nanda¹, Marshall Bern², Sidharth Mohan¹,

Iman Farasat¹, Harsha Gunawardena¹


- 1. J&J Innovative Medicine, Spring House, PA 19477, USA
 - 2. Protein Metrics LLC, Boston, MA 02110, USA



Introduction

High Throughput (HT) Mass spectrometry (MS) has been indispensable in the discovery of small molecules, peptide/mini protein drug modalities to provide accurate molecular masses with very high accuracy and speed. HT ESLMS of antibodies was recently demonstrated by Sawyer et al., PNAS, 2020, 117, 9851-9856. Motivated by this work, we have developed a complete end-to-end (E2E) pipeline coupling RapidFire-MS (RF-MS) data acquisition with real-time informatics and data aggregation for biologics. As a result, we enable the integration of production, analytics, and informatics to screen large panels of biologics, e.g., >10³-10⁴ molecules by streamlining hardware and data automation. We demonstrate the analytical figures of merit of how pipeline delivery of biologics compares to traditional analytical and off-the-bench informatics solutions.

Methods



E2E Automated Sample Preparation, Acquisition and Data Analysis

Figure 1. The structure of the RapidFire automation High-Throughput platform for Biologics Screening 1. LIMS system supports the retrieval of samples

- 2. Automated protein A purification using MARS robotics and robotic hand-off (Future state)
- 3. RapidFire–MS acquisition
- 4. Data severs storing data
- 5. Automated data sweep to Byosphere platform with fully integrated intact MS Data-driven workflows
- 6. Automated export of results and joint reporting of modifications

7&8. Aggregate data with molecule information to build 'In-house' knowledge base (also auto QC)




Figure 2. The RF-MS system can be applied for a typical large molecule (e.g., antibody) analysis. (A) The system enabling data to acquisition rates as fast as 5 seconds per sample. The sample IDs and locations on the well are matched using metadata files.(B) High quality raw MS data were acquired with highthroughput. (C) Accurate mass was deconvoluted with Byos intact mass deconvolution algorithm.




Figure 3. Rapid subunit glycoforms analysis via RapidFire. (A) Diagram of subunit digestion and fragments (B) High quality raw MS data were acquired with high-throughput. (C-E) Accurate masses of each fragment were deconvoluted.



Figure 4. Web-based customizable reports showing relative % of glycoforms and the mass accuracy





Figure 5 RF-MS spectra of multiple antibody modalities run in a batch after PNGAse F deglycosylation

Results and Discussion



<u>Figure 6.</u> RF-MS Batch processing of 96-well plate with masses close to the target mass. (A) The raw data mass spectra of the ten samples. (B) The deconvoluted masses from panel A. (C) The zoom-in image of the ten masses shown the two samples with target mass, three samples with unprocessed Lysin, and five samples with a mass of another target molecule (re-annotation).



Figure 7. Byosphere advanced search capabilities based on meta data attributes

Summary

- Large panels of biologics generated in HT-Protein Expression are screened immediately using a RapidFire coupled with a quadrupole time-of-flight mass spectrometer (RF-MS).
- This E2E workflow to identify hundreds of large molecules in a day with minimal human intervention
- The acquisition is hands-off and significantly faster compared to conventional LC-MS approaches.
- Comparable data quality to LC-MS was obtained.
- The well-designed reporting system shows a comprehensive attributes of biologic molecules
- Enabling the team get an early insight in the quality of biologics in real-time.
- Raw MS data and associated meta data are swept to an automation module in the Byosphere that resides in the J&J cloud server.
- Advanced querying capabilities and quality control of data allows triaging voluminous data sets.

The authors declare no competing financial interest.



